Spatial Biology Microscope Cancer: EVOS S1000, M7000 UK 2026

Published: 13 May 2026 | Last updated: 13 May 2026

What Is Spatial Biology?

Traditional biology looks at cells in isolation. You take a tissue sample, grind it up, and analyse the average signal across millions of cells. This works for many applications, but it misses something critical: where things happen in space.

Spatial biology preserves the physical location of cells within tissue while measuring molecular markers — proteins, RNA, DNA — at single-cell resolution. Instead of asking "what genes are active in this tumour?", spatial biology asks "which immune cells are infiltrating which regions of the tumour, and what are they doing there?"

This shift from bulk analysis to spatially resolved single-cell data is transforming our understanding of disease. Here is why it matters.

The Cancer Breakthrough: Tumour Microenvironments

Cancer is not an uniform mass of identical cells. a tumour contains cancer cells, immune cells, blood vessels, fibroblasts, and extracellular matrix — all interacting in complex spatial patterns. These tumour microenvironments determine whether a patient responds to treatment.

Recent research published in Nature Genetics (2025) demonstrated that spatial signatures — patterns of immune cell infiltration mapped across tumour tissue — can predict which non-small cell lung cancer patients will respond to immunotherapy. The study used multiplexed immunofluorescence to characterise the spatial organisation of tumour-immune interactions, revealing metabolic mechanisms that drive treatment response.

"Non-small cell lung cancer shows variable responses to immunotherapy. Spatial signatures for predicting immunotherapy outcomes using multi-omics reveal that the physical arrangement of immune cells within tumours is as important as their presence."
— Nature Genetics, 2025

Similarly, research in Nature Communications (2026) used spatial transcriptomics to map gastric cancer tissue, identifying lymphocyte-aggregated regions that correlate with patient survival. By understanding where immune cells cluster within tumours, researchers can predict outcomes and design targeted interventions.

Immunotherapy: Why Location Matters

Immune checkpoint inhibitors have transformed cancer treatment, but they only work for 20-40% of patients. The critical question — which patients will benefit? — is increasingly answered through spatial analysis.

Nature Cancer study (2026) on metastatic triple-negative breast cancer showed that the temporal and spatial composition of the tumour microenvironment predicts response to immune checkpoint inhibition. Patients with specific spatial patterns of T-cell infiltration showed dramatically better outcomes.

This matters because it means:

• Better patient selection: Spatial biomarkers can identify who will respond before treatment begins
• Mechanistic understanding: Researchers can see where treatment fails and why
• Drug development: Spatial data reveals new therapeutic targets in the tumour microenvironment

Beyond Cancer: Infectious Disease and Autoimmunity

Spatial biology is not limited to oncology. Researchers are applying these techniques to:

• Infectious disease: Mapping where pathogens localise within tissue, how immune cells respond spatially, and why some infections persist
• Autoimmune disorders: Understanding spatial patterns of immune cell infiltration in rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease
• Neurodegeneration: Characterising cellular neighbourhoods in Alzheimer's and Parkinson's disease tissue

The common thread: context matters. a T-cell next to a cancer cell behaves differently than the same T-cell next to a healthy cell. Spatial biology captures this context.

The Technology: How Spatial Biology Works

Several technologies enable spatial analysis, each with trade-offs:

1. Spatial Transcriptomics (10x Genomics Visium)

Captures RNA sequences while preserving spatial location. Visium places tissue on a slide with barcoded spots, each 55 micrometres across. You get transcriptomic data with ~5-cell resolution. Good for exploratory studies but lacks single-cell precision.

2. Spatial Proteomics (Akoya PhenoCycler-Fusion)

Uses cyclic immunofluorescence to image 100+ protein markers at single-cell resolution. Tissue is stained with antibody panels, imaged, stripped, and restained repeatedly. Each cycle adds more markers, building a comprehensive protein atlas.

3. Integrated Spatial Imaging (EVOS S1000)

a more accessible entry point for spatial biology. The EVOS S1000 performs 9-plex tissue imaging in a single round — no cyclic staining needed. It captures high-resolution images with up to 9 simultaneous fluorescent targets, preserving sample integrity.

Thermo Fisher's application note demonstrates the EVOS S1000 investigating colon adenocarcinoma tumour microenvironment with spatial biology antibody conjugates, showing how researchers can visualise cellular neighbourhoods without complex infrastructure.

Choosing the Right Tool

Platform	Markers	Resolution	Speed	Best For
10x Visium	Whole transcriptome	~5 cells	Days	Discovery, exploratory
Akoya PhenoCycler	100+ proteins	Single-cell	Fast	High-throughput, clinical
EVOS S1000	9 targets	Cellular	Hours	Accessibility, teaching

The Future: Spatial Biology in the Clinic

Spatial biology is moving from research tool to clinical application. Pathologists are beginning to use spatial signatures for:

• Cancer subtyping: Identifying aggressive tumour regions that require different treatment
• Treatment selection: Predicting immunotherapy response before first dose
• Drug development: Understanding why drugs fail in specific tissue contexts
• Companion diagnostics: Spatial biomarkers as FDA-approved tests

The Akoya-Enable Medicine spatial proteomics atlas, launched in 2025, represents the largest commercially available single-cell spatial dataset — over 8 million cells across multiple cancer types. This resource accelerates biomarker discovery by letting researchers compare their spatial data against validated reference atlases.

Conclusion

Spatial biology is not just an incremental improvement — it is a fundamental shift in how we understand disease. By preserving the physical context of molecular data, researchers can see patterns that bulk analysis misses entirely.

For cancer research, this means predicting treatment response from tissue architecture. For infectious disease, it means understanding why pathogens persist in specific tissue niches. For autoimmune disorders, it means mapping the spatial logic of immune cell infiltration.

The technology is maturing rapidly. Platforms like the Akoya PhenoCycler-Fusion bring high-throughput spatial proteomics within reach of clinical studies, while the EVOS S1000 makes spatial imaging accessible for smaller labs and teaching environments. Together, these tools are democratising spatial biology — and accelerating the pace of disease research.

← Back to homepage | View all blog posts →